前沿速览043期| CAR-T治B淋 前沿览新知
01
CAR-T细胞治疗持久缓解与细胞毒性初始T细胞的活化增强及克隆扩增相关
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire
第一作者：Cheloni G
Nat Commun (IF=14.7). 2025 May 23;16(1):4819.
全文网址：https://www.nature.com/articles/s41467-025-59904-x
02
原发或继发中枢神经系统淋巴瘤患者接受CAR-T细胞治疗的疗效与安全性：一项由EBMT及GoCART联盟开展的研究
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
第一作者：Ossami Saidy A
Hemasphere (IF=11.9). 2025 May 21;9(5):e70146.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/hem3.70146
03
CAR-T细胞扩增与全身炎症反应对大B细胞淋巴瘤疗效的不同影响：一项多中心CART SIE研究
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
第一作者：Magni M
Haematologica (IF=8.2). 2025 May 29.
全文网址：https://haematologica.org/article/view/12086
04
美国复发/难治性弥漫大B细胞淋巴瘤患者接受CAR-T细胞治疗的不平等性：基于SEER-Medicare数据分析
Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data Analysis
第一作者：Chung A
Blood Adv (IF=7.4). 2025 May 16:bloodadvances.2024015634.
全文网址：https://ashpublications.org/bloodadvances/article-lookup/doi/10.1182/bloodadvances.2024015634
05
含CD28和TLR2胞内结构域的第三代CD19-CAR-T细胞治疗中枢神经系统受累B细胞恶性肿瘤的疗效与安全性：一项关键试验结果
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial
第一作者：He B
J Transl Med (IF=6.1). 2025 May 27;23(1):594. doi: 10.1186/s12967-025-06608-x.
全文网址：https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06608-x
06
双靶点CD19/20 CAR-T与单靶点CD19 CAR-T治疗复发/难治性弥漫大B细胞淋巴瘤的疗效及不良事件比较：一项单中心回顾性研究
Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study
第一作者：Xue B
Front Immunol (IF=5.7). 2025 May 6;16:1582944.
全文网址：https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1582944/full
07
回输前达到完全缓解DLBCL患者的CAR-T细胞扩增强劲，预后更优
Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion
第一作者：Hanajiri R
Br J Haematol (IF=5.1). 2025 May 25.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.20186
08
复发或难治性大B细胞淋巴瘤的管理：英国血液学会指南
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline
第一作者：Chaganti S
Br J Haematol (IF=5.1). 2025 May 19.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.20129
09
日本患者接受规格外tisagenlecleucel治疗的临床结局：一项3b期试验
Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b
第一作者：Kato K
Cytotherapy (IF=3.7). 2025 Apr 18:S1465-3249(25)00685-1.
全文网址：https://www.isct-cytotherapy.org/article/S1465-3249(25)00685-1/fulltext
10
与年龄相关的烟酰胺腺嘌呤二核苷酸下降导致CAR-T细胞失效
Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure
第一作者：Hope HC
Nat Cancer (IF=23.5). 2025 May 20.
全文网址：https://www.nature.com/articles/s43018-025-00982-7
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.6-3 valid until 2027.6
供稿与审核：临床开发与医学部